From GlobeNewswire: 2025-02-13 06:40:00

Recordati S.p.A. has reported a 12.4% increase in net revenue for FY 2024, totaling € 2,341.6 million. EBITDA also saw a 12.5% growth, reaching € 865.8 million, with adjusted net income up by 8.4% to € 568.9 million. The company’s free cash flow increased to € 535.1 million, and net debt was just below 2.4x EBITDA. Recordati has raised peak year sales targets for key Rare Diseases products, including Isturisa®, Signifor®, Qarziba®/Sylvant®, and Enjaymo®. Sustainability efforts have been recognized, and the company’s financial targets for FY 2025 are optimistic.

In 2024, Recordati experienced significant growth across its business units, with Specialty & Primary Care revenue growing by 10.3% and Rare Diseases revenue increasing by 16.7%. The company’s focus on ESG strategy led to recognition in several ESG indices and ratings. Recordati also completed the acquisition of Enjaymo® from Sanofi, a biologic for cold agglutinin disease. The company submitted regulatory applications for label extensions of Isturisa® and received approval in China. The three-year plan and mid-term financial targets will be updated soon.

An increase in net revenue and EBITDA for FY 2024, along with the recognition of ESG efforts and successful acquisitions, have positioned Recordati for continued growth in 2025. The company’s focus on Rare Diseases products and sustainability is driving its success. Recordati’s commitment to delivering innovative treatments and maintaining financial stability is reflected in its raised sales targets and positive outlook for the future.



Read more at GlobeNewswire: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE